Jinyu Bio Financials
| 600201 Stock | 7.37 0.05 0.68% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 316.5 M | 324.8 M |
|
|
Jinyu | Select Account or Indicator |
Understanding current and past Jinyu Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Jinyu Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Jinyu Bio's assets may result in an increase in income on the income statement.
Please note, the presentation of Jinyu Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Jinyu Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Jinyu Bio's management manipulating its earnings.
Jinyu Bio Stock Summary
Jinyu Bio competes with Industrial, China Construction, Bank of China, Agricultural Bank, and PetroChina. Jinyu Bio is entity of China. It is traded as Stock on SHG exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| ISIN | CNE000000Y37 |
| Business Address | Shaerqin Industrial Park, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.jinyu.com.cn |
| Phone | 86 47 1653 9434 |
You should never invest in Jinyu Bio without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Jinyu Stock, because this is throwing your money away. Analyzing the key information contained in Jinyu Bio's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Jinyu Bio Key Financial Ratios
Jinyu Bio's financial ratios allow both analysts and investors to convert raw data from Jinyu Bio's financial statements into concise, actionable information that can be used to evaluate the performance of Jinyu Bio over time and compare it to other companies across industries.| Revenue | 1.6 B | ||||
| Gross Profit | 831.37 M | ||||
| EBITDA | 281.76 M | ||||
| Net Income | 283.63 M | ||||
| Total Asset | 6.87 B |
Jinyu Bio Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 5.6B | 6.3B | 6.6B | 6.4B | 6.9B | 7.2B | |
| Other Current Liab | 156.5M | 269.2M | 238.7M | 194.4M | 63.6M | 60.4M | |
| Other Liab | 153.7M | 335.8M | 354.4M | 380.6M | 437.7M | 459.6M | |
| Retained Earnings | 2.8B | 3.1B | 3.4B | 3.5B | 3.2B | 3.3B | |
| Accounts Payable | 295.2M | 330.3M | 347.1M | 354.4M | 324.4M | 176.8M | |
| Cash | 1.1B | 1.5B | 1.3B | 1.4B | 1.7B | 884.3M | |
| Other Assets | 473.1M | 447.9M | 483.2M | 513.8M | 590.9M | 620.5M | |
| Net Receivables | 643.0M | 605.6M | 729.1M | 763.3M | 857.5M | 900.4M | |
| Inventory | 245.3M | 350.7M | 317.7M | 333.5M | 322.3M | 388.8M | |
| Other Current Assets | 23.2M | 16.1M | 19.4M | 19.8M | 23.9M | 35.7M | |
| Total Liab | 716.8M | 1.0B | 1.0B | 1.0B | 1.2B | 720.8M | |
| Intangible Assets | 519.7M | 576.7M | 648.5M | 668.5M | 728.8M | 765.3M | |
| Net Tangible Assets | 4.2B | 4.5B | 4.8B | 4.7B | 5.4B | 4.4B | |
| Total Current Assets | 2.7B | 3.2B | 2.8B | 2.7B | 3.0B | 3.3B | |
| Net Invested Capital | 4.7B | 5.0B | 5.3B | 5.1B | 5.4B | 5.5B | |
| Net Working Capital | 2.1B | 2.5B | 2.1B | 2.0B | 2.2B | 1.9B | |
| Good Will | 130.8M | 134.3M | 94.5M | 29.5M | 11.4M | 10.8M |
Jinyu Bio Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 9.2M | 974.7K | 42.6K | 4.8M | 53.4K | 50.7K | |
| Total Revenue | 1.1B | 1.6B | 1.8B | 1.5B | 1.6B | 1.0B | |
| Operating Income | 291.8M | 439.9M | 426.3M | 297.7M | 324.8M | 316.5M | |
| Cost Of Revenue | 424.6M | 607.5M | 677.1M | 685.3M | 652.2M | 378.1M | |
| Income Before Tax | 253.5M | 476.2M | 413.3M | 245.6M | 315.8M | 312.9M | |
| Net Income | 221.0M | 406.2M | 382.3M | 210.7M | 283.6M | 263.7M | |
| Income Tax Expense | 26.6M | 53.8M | 24.3M | 45.4M | 52.3M | 49.2M | |
| Minority Interest | 221.8M | 281.3M | (6.7M) | 10.5M | 6.5M | 6.2M | |
| Research Development | 86.7M | 130.8M | 165.9M | 133.8M | 143.5M | 110.1M | |
| Gross Profit | 702.2M | 974.4M | 1.1B | 843.4M | 946.0M | 850.7M | |
| Ebit | 211.7M | 407.0M | 394.2M | 252.0M | 226.8M | 442.5M | |
| Tax Provision | 26.6M | 53.8M | 24.3M | 45.4M | 38.7M | 62.3M | |
| Net Interest Income | 17.8M | 19.8M | 40.5M | 46.0M | 56.2M | 36.6M | |
| Interest Income | 27.5M | 21.1M | 41.2M | 50.9M | 56.5M | 39.6M | |
| Ebitda | 369.8M | 650.8M | 604.9M | 450.6M | 405.5M | 553.7M |
Jinyu Bio Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Jinyu Bio Technology. It measures of how well Jinyu is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Jinyu Bio brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Jinyu had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Jinyu Bio has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Dividends Paid | 403.4M | 67.1M | 134.2M | 124.4M | 66.8M | 104.3M | |
| Capital Expenditures | 307.4M | 228.3M | 372.7M | 190.1M | 273.2M | 166.3M | |
| Net Income | 221.0M | 406.2M | 382.3M | 210.7M | 283.6M | 263.7M | |
| Change To Inventory | 27.4M | (112.1M) | 25.9M | (20.5M) | 8.5M | 9.0M | |
| Investments | 680.1M | (205.0M) | (66.1M) | 210.6M | (740.1M) | (703.1M) | |
| Change In Cash | (28.1M) | 334.6M | (138.4M) | 84.1M | (213.9M) | (203.2M) | |
| Net Borrowings | 37.5M | (40.1M) | (504.7K) | 59.2M | 68.1M | 71.5M | |
| Depreciation | 107.1M | 173.6M | 191.6M | 196.9M | 189.3M | 140.3M | |
| Change To Netincome | 52.8M | (382.5K) | 46.7M | 51.4M | 59.1M | 62.1M | |
| End Period Cash Flow | 986.4M | 1.3B | 1.2B | 1.3B | 1.1B | 1.1B | |
| Free Cash Flow | 97.9M | 471.3M | 160.4M | 154.5M | 141.7M | 159.1M | |
| Other Non Cash Items | 9.7M | 1.8M | (13.5M) | (27.9M) | (32.1M) | (30.5M) |
Jinyu Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Jinyu Bio's current stock value. Our valuation model uses many indicators to compare Jinyu Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jinyu Bio competition to find correlations between indicators driving Jinyu Bio's intrinsic value. More Info.Jinyu Bio Technology Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.34 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Jinyu Bio Technology Co is roughly 2.96 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Jinyu Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jinyu Bio's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Jinyu Bio Technology Systematic Risk
Jinyu Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Jinyu Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-two with a total number of output elements of nineteen. The Beta measures systematic risk based on how returns on Jinyu Bio Technology correlated with the market. If Beta is less than 0 Jinyu Bio generally moves in the opposite direction as compared to the market. If Jinyu Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Jinyu Bio Technology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Jinyu Bio is generally in the same direction as the market. If Beta > 1 Jinyu Bio moves generally in the same direction as, but more than the movement of the benchmark.
Jinyu Bio Technology Co Total Assets Over Time
Jinyu Bio Thematic Clasifications
Jinyu Bio Technology Co is part of Computers investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Computers industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Computers industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Computers | View |
Jinyu Bio December 12, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Jinyu Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Jinyu Bio Technology Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Jinyu Bio Technology Co based on widely used predictive technical indicators. In general, we focus on analyzing Jinyu Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Jinyu Bio's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.59 | |||
| Information Ratio | 0.0802 | |||
| Maximum Drawdown | 17.03 | |||
| Value At Risk | (3.85) | |||
| Potential Upside | 4.72 |
Complementary Tools for Jinyu Stock analysis
When running Jinyu Bio's price analysis, check to measure Jinyu Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jinyu Bio is operating at the current time. Most of Jinyu Bio's value examination focuses on studying past and present price action to predict the probability of Jinyu Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jinyu Bio's price. Additionally, you may evaluate how the addition of Jinyu Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |